BIOGERM.BIOGERM, founded in 2017, is a high-tech company specializing in precise and rapid disease diagnostics. It integrates the R&D, production, sales, and service of reagents and equipment. Driven by robust R&D innovation, the company has established seven major technology platforms and founded a Health Research Institute dedicated to breakthroughs in foundational technologies. As of July 2025, its product pipeline is exceptionally extensive, having developed over 600 diagnostic reagents and obtained more than 200 domestic and international medical device registrations. Its business spans dozens of countries worldwide. Guided by the principle of “Fast, Accurate, Simple, and Affordable,” BIOGERM has become a leading enterprise in China's infectious pathogen diagnostics sector, serving over 5,500 end-users. The company prioritizes intellectual property, holding over 100 patents and software copyrights. Moving forward, BIOGERM is committed to its mission of “empowering physicians' diagnostics and enhancing quality of life,” advancing toward its goal of becoming a world-class diagnostic expert. Its core products encompass clinical and research diagnostic reagents, instrumentation, sequencing services, and comprehensive laboratory solutions.
